Anti-PD-1 therapy shows potential for recurrent, advanced MSI-H endometrial cancer

October 25, 2018 1:25 PM | Anonymous

October 25, 2018, Cure Today 

The anti-PD-1 monoclonal antibody TSR-042 appeared to be safe and effective in the treatment of patients with microsatellite-high (MSI-H) endometrial cancer, according to preliminary results presented at the European Society for Medical Oncology (ESMO)'s 2018 Congress.  

Read more.

Powered by Wild Apricot Membership Software